MARKET

ZYME

ZYME

Zymeworks
NASDAQ
23.88
+0.62
+2.67%
Pre Market: 24.16 +0.28 +1.15% 04:42 06/24 EDT
OPEN
22.90
PREV CLOSE
23.26
HIGH
24.27
LOW
22.90
VOLUME
93
TURNOVER
0
52 WEEK HIGH
29.75
52 WEEK LOW
11.51
MARKET CAP
1.74B
P/E (TTM)
-17.4664
1D
5D
1M
3M
1Y
5Y
1D
ZW191’s Broad Phase 1 Activity in Ovarian Cancer Could Be A Game Changer For Zymeworks (ZYME)
Simply Wall St · 18h ago
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Maze Therapeutics, Inc. (MAZE) and Universal Health (UHS)
TipRanks · 1d ago
H.C. Wainwright Sticks to Their Buy Rating for Zymeworks (ZYME)
TipRanks · 1d ago
Weekly Report: what happened at ZYME last week (0615-0619)?
Weekly Report · 1d ago
Zymeworks (ZYME) Stock Could Be 42.3% Undervalued After Cryo EM Breakthrough
Simply Wall St · 3d ago
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Amylyx Pharmaceuticals Inc (AMLX) and AbCellera Biologics (ABCL)
TipRanks · 5d ago
Zymeworks partners with Gandeeva to generate cryo-EM structural data for antibody discovery
PUBT · 5d ago
Did Strong ZW191 Phase 1 Data in Resistant Gynecologic Cancers Just Shift Zymeworks' (ZYME) Investment Narrative?
Simply Wall St · 06/15 23:25
More
About ZYME
Zymeworks Inc. is a biotechnology company. The Company is engaged in managing a portfolio of healthcare assets and developing a pipeline of multifunctional biotherapeutics to improve the standard of care for conditions, including cancer, inflammation, and autoimmune disease. Its antibody-drug conjugates (ADCs) include ZW191, ZW251, and ZW220. ZW191 is a clinical-stage ADC that targets folate receptor alpha-expressing tumors including ovarian cancer, endometrial cancer, and non-small cell lung cancer (NSCLC), which is built using bystander-active, TOPO1i payload technology, ZD06519. ZW251 is a clinical-stage ADC molecule designed for the treatment of glypican 3 (GPC3)-expressing hepatocellular carcinoma (HCC). ZW220 is an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer, built using bystander active TOPO1i payload technology, ZD06519. Its therapeutic platforms can be used to develop multifunctional fit-for-purpose biotherapeutics with bispecific capabilities.

Webull offers Zymeworks Inc stock information, including NASDAQ: ZYME real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZYME stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZYME stock methods without spending real money on the virtual paper trading platform.